Veru (VERU) Q2 2025 Earnings Call May 08, 2025 08:00 AM ET Speaker0 After this morning's discussion, there will be an opportunity to ask questions. Please note that this event is being recorded. I would now like to turn the conference call over to Mr. Sam Fish, Veru Inc. Executive Director, Investor Relations and Corporate Communications. Please go ahead, sir. Speaker1 Statements made on this conference call may be forward looking statements. Forward looking statements may include, but are not necessarily l ...

Select Water Solutions (WTTR) Q1 2025 Earnings Call May 07, 2025 11:00 AM ET Speaker0 Greetings, and welcome to the Select Water Solutions twenty twenty five First Quarter Earnings Conference Call. At this time, all participants are in a listen only mode. A question and answer session will follow the formal presentation. As a reminder, this conference is being recorded. It is now my pleasure to introduce your host, Garrett Williams, Vice President of Corporate Finance and Investor Relations. Thank you, sir. ...

Core Insights - Viking Therapeutics is positioned to potentially capitalize on a rapidly growing weight loss drug market projected to reach $150 billion by the early 2030s [1][7] - The company is focused on developing its lead drug candidate, VK2735, which is a dual GLP-1 and GIP receptor agonist aimed at treating obesity [8] - Viking's stock has experienced significant volatility since its IPO, reflecting the inherent risks associated with pre-revenue biopharmaceutical companies [3][6] Company Overview - Viking Therapeutics is a clinical-stage biopharmaceutical company with a narrow pipeline, currently developing two compounds in late-stage clinical trials [6] - The company has no sales or profits, which is typical for pre-revenue firms in the pharmaceutical sector [4] - Viking has a market capitalization of $2.9 billion, indicating potential investment upside if it successfully penetrates the weight loss market [10] Drug Development and Trials - VK2735 has shown promising results in its phase 2 trials, with patients losing up to 14.7% of their body weight in 13 weeks [9] - The company is conducting both injectable and oral versions of VK2735, with the injectable version performing well in trials [9] - Viking is preparing to initiate phase 3 trials for VK2735, with expectations for FDA approval potentially by mid- to late-2028 [10] Financial Position - Viking Therapeutics has over $851 million in cash and no debt, providing a solid financial foundation for ongoing development [11] - The company's cash burn rate was approximately $88 million over the past year, suggesting it has sufficient funding for several years [11]

Novo Nordisk A/S NVO announced that CVS Health Inc’s CVS CVS Caremark, a Pharmacy Benefit Manager (PBM), has decided that Wegovy (semaglutide) injection 2.4 mg will soon be the preferred GLP-1 medicine on its largest commercial template formularies.This change will take effect on July 1, 2025. “We believe in the unique benefits of Wegovy and the difference this medicine can make for patients seeking treatment,” said Dave Moore, executive vice president of U.S. Operations and president of Novo Nordisk Inc.In ...

The "Wegovy" brand slimming syringe is sold in the Achat pharmacy in Mitte. The "Wegovy" slimming syringe has been available in Germany for a year.CVS Health on Thursday said it will significantly expand access to the blockbuster weight loss drug Wegovy for patients covered by its pharmacy benefit manager, Caremark. Starting July 1, Caremark will prioritize Wegovy on its formularies — or lists of covered drugs — making it the preferred GLP-1 drug for obesity. The move is part of a new partnership between Ca ...

Core Viewpoint - Viking Therapeutics has experienced a significant decline in stock price in 2025, down 35% year to date, despite a strong performance in 2024 due to promising clinical progress [1][2][3] Group 1: Company Performance - The company's leading candidate, VK2735, an investigational GLP-1 weight loss therapy, showed excellent phase 2 results and is expected to advance to phase 3 studies soon [5] - Viking's market cap is approximately $3 billion, and it is considered one of the more promising bets in the weight loss therapy sector, despite competition from larger companies like Eli Lilly and Novo Nordisk [8][6] - The company is also developing VK2809 for metabolic dysfunction-associated steatohepatitis (MASH), which has also passed phase 2 studies, and VK0214 for X-linked adrenoleukodystrophy, which has completed phase 1 studies [9][10] Group 2: Financial Position - Viking Therapeutics ended the first quarter with $852 million in cash and equivalents, down from $903 million at the end of 2024, indicating a solid financial position to support ongoing studies [11] - The company is expected to access additional funding easily due to its clinical progress, which should mitigate any immediate funding concerns [11] Group 3: Market Context - The weight loss market is experiencing rapid growth, with sales of existing therapies increasing significantly, and analysts predict continued growth in this sector at least until the early 2030s [7] - Despite the influx of investigational weight loss therapies, most have shown modest results, making Viking's promising data stand out in the competitive landscape [8]

Big pharmaceutical companies as well as smaller biotechs have been hoping to score a win in one of today's highest-growth treatment areas: and that's weight loss. Analysts forecast a compound annual growth rate in the double digits from today over the next several years, with the market reaching $100 billion to $130 billion in the early 2030s.Today, Eli Lilly and Novo Nordisk dominate with their well-known treatments: Lilly makes tirzepatide, commercialized as Mounjaro for type 2 diabetes and as Zepbound fo ...

Novo Nordisk A/S NVO and Hims & Hers Health, Inc. HIMS announced a long-term collaboration on Tuesday.In March, Novo Nordisk introduced NovoCare Pharmacy, a direct-to-patient delivery service to improve access to Wegovy (semaglutide) for cash-paying patients.Americans can now access NovoCare Pharmacy directly through the Hims & Hers platform. A bundled offering of all dose strengths of Wegovy and a Hims & Hers membership, which includes access to 24/7 care, ongoing clinical support, and nutrition guidance.I ...

Summary ⚈ HIMS stock surged up to 45% after announcing a partnership with Novo Nordisk to offer Wegovy through its platform. The American firm will now offer prescriptions for the drug starting at $599 per month via NovoCare Pharmacy. Previously, Wegovy was available only through local pharmacies or from Novo's NovoCare Pharmacy program. The partnership unlocks a potentially massive new revenue stream for Hims & Hers, which has been steadily growing its subscription-based health offerings. By integrating We ...

Core Insights - WeightWatchers has announced a pharmacy integration with Gifthealth to enhance access to Zepbound® for its clinic members [1][2] - The integration aims to streamline the fulfillment process and improve medication visibility for eligible members [2][3] Company Overview - WeightWatchers is a leader in science-backed weight management, providing a holistic model of care that includes clinical interventions and community support [4] - The company has been transforming lives for over 60 years, empowering millions of members to build healthy habits [4] Integration Details - The integration with Gifthealth allows for real-time prescription tracking and streamlined access to Zepbound® vials for self-pay patients without insurance [2][3] - Zepbound® usage among WeightWatchers Clinic members has increased significantly, with 33% currently using it and prescriptions for Zepbound vials rising over 100% recently [3] Clinical Impact - A study of 3,260 WeightWatchers Clinic patients showed an average weight loss of 21% at 12 months, indicating the effectiveness of combining GLP-1 medications like Zepbound with WeightWatchers' lifestyle support [3]